| Next-generation treatments for mental disorders. | |
| | |
MedLine Citation:
|
PMID: 23052292 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
There has been a steady retreat by the private sector away from developing medications for mental disorders. This retreat comes just as research is identifying new molecular targets, new clinical targets, and new uses of current treatments that may serve as the basis for the next generation of treatments for mental disorders. |
| | |
Authors:
|
Thomas R Insel |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Science translational medicine Volume: 4 ISSN: 1946-6242 ISO Abbreviation: Sci Transl Med Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101505086 Medline TA: Sci Transl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 155ps19 Citation Subset: IM |
Affiliation:
|
National Institute of Mental Health, Bethesda, MD 20892, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revolution stalled.
Next Document: Human neural stem cells induce functional myelination in mice with severe dysmyelination.